Tarsus Pharmaceuticals (TARS) Interest Coverage Ratio (2019 - 2026)
Tarsus Pharmaceuticals' (TARS) quarterly Interest Coverage Ratio came in at 2.88 in Q1 2026, up 75.77% year-on-year from 1.64 in Q1 2025, and up 20.14% quarter-over-quarter from 3.6 in Q4 2025.
Tarsus Pharmaceuticals (TARS) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Interest Coverage Ratio history runs 8 years deep, the most recent figure standing at 2.88 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 75.77% year-over-year to 2.88 in Q1 2026; TTM through Mar 2026 was 5.76, a 51.85% increase from a year earlier, with the FY2025 full-year figure at 0.23, up 65.99% from the prior year.
- Interest Coverage Ratio improved to 2.88 in Q1 2026 per TARS's latest filing, from 3.6 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.21 in Q2 2025 and bottomed at 89.65 in Q4 2022.
- The 5-year median for Interest Coverage Ratio is 15.79 (2024), against an average of 27.43.
- Across the five-year window, Interest Coverage Ratio plunged 319.36% in 2023 and surged 98.67% in 2025, its largest moves.
- Year by year, Interest Coverage Ratio stood at 89.65 in 2022, then surged by 49.87% to 44.94 in 2023, then jumped by 76.99% to 10.34 in 2024, then surged by 65.17% to 3.6 in 2025, then climbed by 20.14% to 2.88 in 2026.
- Per Business Quant, the three latest TARS Interest Coverage Ratio figures stand at 2.88 (Q1 2026), 3.6 (Q4 2025), and 6.41 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Tarsus Pharmaceuticals | 2.52 Bn | 2.41 Bn | 152.66 Mn | -2.88 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.88 |
| Dec 31, 2025 | -3.60 |
| Sep 30, 2025 | -6.41 |
| Jun 30, 2025 | -0.21 |
| Mar 31, 2025 | -11.88 |
| Dec 31, 2024 | -10.34 |
| Sep 30, 2024 | -10.29 |
| Jun 30, 2024 | -15.79 |
| Mar 31, 2024 | -38.34 |
| Dec 31, 2023 | -44.94 |
| Sep 30, 2023 | -47.71 |
| Jun 30, 2023 | -40.27 |
| Mar 31, 2023 | -36.48 |
| Dec 31, 2022 | -89.65 |
| Sep 30, 2022 | -36.19 |
| Jun 30, 2022 | -9.60 |
| Mar 31, 2022 | -61.78 |
| Jun 30, 2021 | 87.73 |
| Mar 31, 2021 | 108.22 |
| Dec 31, 2020 | -0.17 |